Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
复制标题
DOI：
10.1186/bcr3616
复制
发表时间：
2014-02-14
期刊：
影响因子：
--
通讯作者：
Hofbauer LC
中科院分区：
文献类型：
--
作者：
Rachner TD;Göbel A;Thiele S;Rauner M;Benad-Mehner P;Hadji P;Bauer T;Muders MH;Baretton GB;Jakob F;Ebert R;Bornhäuser M;Schem C;Hofbauer LC
氨基双膦酸盐和他汀类药物抑制甲羟戊酸途径，并可能发挥抗肿瘤作用。Wnt抑制剂dickkopf-1 （DKK-1）通过抑制成骨细胞功能促进骨溶解病变，并被认为是多种癌症的不良标志物。我们评估了甲羟戊酸途径抑制对成骨性乳腺癌中DKK-1表达的影响。研究了双膦酸盐和他汀类药物在人乳腺癌细胞系中对DKK-1的调控作用，并分析了甲羟戊酸途径及其下游靶点的作用。此外，我们还在mC2C12细胞中研究了乳腺癌细胞通过DKK-1调节成骨细胞形成的潜力。通过分析暴露于双膦酸盐的乳腺癌妇女组织和血清中的DKK-1表达，验证了临床相关性。DKK-1在受体阴性乳腺癌细胞系中高表达。与健康对照相比，受体阴性肿瘤患者在组织和血清水平上显示DKK-1水平升高。唑来膦酸和阿托伐他汀通过抑制CDC42和Rho的香叶酰化来抑制DKK-1。在大量表达DKK-1的溶骨性乳腺癌细胞系中，DKK-1的调控作用最强。抑制DKK-1抑制了乳腺癌细胞阻断wnt3a诱导的成骨前细胞C2C12中碱性磷酸盐和骨保护素产生的能力。与体外实验数据一致，用唑来膦酸治疗乳腺癌患者12个月后，DKK-1水平平均降低了60%。DKK-1是甲羟戊酸途径的新靶点，在乳腺癌中被唑来膦酸和阿托伐他汀抑制。
Amino-bisphosphonates and statins inhibit the mevalonate pathway, and may exert anti-tumor effects. The Wnt inhibitor dickkopf-1 (DKK-1) promotes osteolytic bone lesions by inhibiting osteoblast functions and has been implicated as an adverse marker in multiple cancers. We assessed the effects of mevalonate pathway inhibition on DKK-1 expression in osteotropic breast cancer. Regulation of DKK-1 by bisphosphonates and statins was assessed in human breast cancer cell lines, and the role of the mevalonate pathway and downstream targets was analyzed. Moreover, the potential of breast cancer cells to modulate osteoblastogenesis via DKK-1 was studied in mC2C12 cells. Clinical relevance was validated by analyzing DKK-1 expression in the tissue and serum of women with breast cancer exposed to bisphosphonates. DKK-1 was highly expressed in receptor-negative breast cancer cell lines. Patients with receptor-negative tumors displayed elevated levels of DKK-1 at the tissue and serum level compared to healthy controls. Zoledronic acid and atorvastatin potently suppressed DKK-1 in vitro by inhibiting geranylgeranylation of CDC42 and Rho. Regulation of DKK-1 was strongest in osteolytic breast cancer cell lines with abundant DKK-1 expression. Suppression of DKK-1 inhibited the ability of breast cancer cells to block WNT3A-induced production of alkaline phosphates and bone-protective osteoprotegerin in preosteoblastic C2C12 cells. In line with the in vitro data, treatment of breast cancer patients with zoledronic acid decreased DKK-1 levels by a mean of 60% after 12 months of treatment. DKK-1 is a novel target of the mevalonate pathway that is suppressed by zoledronic acid and atorvastatin in breast cancer.
登录
查看更多内容
影响因子：
3.4
作者：
Coleman RE;Lipton A;Costa L;Cook RJ;Lee KA;Saad F;Brown JE;Terpos E;Major PP;Kohno N;Smith M;Body JJ
通讯作者：
Body JJ
影响因子：
2.8
作者：
Hall, Christopher L.;Daignault, Stephanie D.;Shah, Rajal B.;Pienta, Kenneth J.;Keller, Evan T.
通讯作者：
Keller, Evan T.
影响因子：
3.1
作者：
Rogers, Michael J.
通讯作者：
Rogers, Michael J.
影响因子：
6.2
作者：
Luckman, SP;Hughes, DE;Rogers, MJ
通讯作者：
Rogers, MJ
影响因子：
158.5
作者：
Coleman, Robert E.;Marshall, Helen;Bell, Richard
通讯作者：
Bell, Richard